Streptokinase
Complex of catalytic domain of human plasmin and streptokinase | |
| Clinical data | |
|---|---|
| Trade names | Fibrion |
| Other names | SK |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Intravenous |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ECHA InfoCard | 100.029.667 |
| Chemical and physical data | |
| Formula | C2100H3278N566O669S4 |
| Molar mass | 47286.86 g·mol−1 |
Streptokinase is a thrombolytic medication activating plasminogen by nonenzymatic mechanism. As a medication it is used to break down clots in some cases of myocardial infarction (heart attack), pulmonary embolism, and arterial thromboembolism. The type of heart attack it is used in is an ST elevation myocardial infarction (STEMI). It is given by injection into a vein.
Side effects include nausea, bleeding, low blood pressure, and allergic reactions. A second use in a person's lifetime is not recommended. While no harm has been found with use in pregnancy, it has not been well studied in this group. Streptokinase is in the antithrombotic family of medications and works by turning on the fibrinolytic system.
Streptokinase was discovered in 1933 from beta-hemolytic streptococci. It is on the World Health Organization's List of Essential Medicines. It is no longer commercially available in the United States.